Janux Therapeutics, Inc.
JANX evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Market Cap:
- $1.23B
- Lead Asset:
- JANX007 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for JANX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · JANX
Janux Therapeutics is a publicly traded biotechnology company developing TRACTr, TRACIr, and ARM platform-based therapies for oncology, with lead programs JANX007 and JANX008 in Phase 1/1b clinical trials for metastatic castration-resistant prostate cancer and solid tumors.
Key risk: Cash runway
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.23B
Cash Runway
—
Lead Asset
JANX007 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 8 clinical trials for Janux Therapeutics, Inc..
Janux Therapeutics is a publicly traded biotechnology company developing TRACTr, TRACIr, and ARM platform-based therapies for oncology, with lead programs JANX007 and JANX008 in Phase 1/1b clinical trials for metastatic castration-resistant prostate cancer and solid tumors.
- Cash & equivalents of $27.8M as of 2026-06-30 [sec]
- Total revenue of $10.3M and net income of -$22.0M as of 2026-06-30 [sec]
- Shareholders' equity of $928.0M as of 2026-06-30 [sec]
- Lead program JANX007 advanced to Phase 1b expansion cohorts in taxane-naïve mCRPC as of May 2025 [sec_mda · as of 2026-02-26]
- First patient dosed in Phase 1 trial of JANX013 with JANX007 for metastatic castration-resistant prostate cancer as of 2026-09-27 [news · published 2026-09-27]
What works
- JANX007 demonstrated durability in both QW and Q2W Phase 1a expansions with a manageable safety profile and CRS primarily limited to cycle 1 and grades 1 and 2 [sec_mda · as of 2026-02-26]
- Preliminary Phase 1b data in taxane-naïve patients showed rapid and deep PSA reductions with primarily grade 1 CRS [sec_mda · as of 2026-02-26]
- The company has initiated multiple Phase 1b expansion cohorts to evaluate JANX007 in clinically relevant patient populations, including combination with darolutamide and post-PARP inhibitor therapy [sec_mda · as of 2026-02-26]
What to weigh
- The company reported a net loss of $22.0M as of 2026-06-30 [sec]
- Cash & equivalents of $27.8M as of 2026-06-30 may be limited relative to ongoing clinical trial costs [sec]
- The process of testing product candidates in clinical trials is costly and the timing of progress and expenses is uncertain, with potential to deplete capital resources sooner than expected [sec_mda · as of 2026-08-06]
- JANX share price showed a 1-month return down 9.6% and a 7-day move down 1.75% as of 2026-09-27 [news · published 2026-09-27]
From the filings
Quoted directly from source documents.
JANX007 safety profile
“JANX007 demonstrated a manageable safety profile with CRS primarily limited to cycle 1 and grades 1 and 2.”
SEC MD&A · February 26, 2026
Phase 1b expansion cohorts initiated
“we initiated the first of our planned Phase 1b expansion cohorts designed to further characterize JANX007 and inform potential registrational development strategies.”
SEC MD&A · February 26, 2026
First patient dosed in JANX013 trial
“Janux Therapeutics (JANX) just hit a clinical milestone, dosing the first patient in its Phase 1 trial of JANX013 with JANX007 for metastatic castration-resistant prostate cancer.”
News · September 27, 2026
Capital depletion risk
“we could deplete our capital resources sooner than we expect.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2022-09-15 · Phase 1 start for JANX007 in metastatic castration-resistant prostate cancer — Initiation of the Phase 1 open-label multicenter study of JANX007 in subjects with metastatic castration-resistant prostate cancer.
- 2023-04-19 · Phase 1/1b start for JANX008 in advanced or metastatic solid tumors — Initiation of the open-label multicenter Phase 1/1b study of JANX008 in subjects with advanced or metastatic solid tumor malignancies.
- 2026-02-16 · Phase 1 start for JANX013 with JANX007 — Initiation of a Phase 1 open-label study for JANX013 in combination with JANX007.
Risks & what to watch (4)›
Key risks
- Cash runway — Cash & equivalents of $27.8M as of 2026-06-30 may be insufficient to fund ongoing clinical trials without additional financing [sec]
- Clinical trial uncertainty — Costly and uncertain timing of clinical trials could deplete capital resources sooner than expected [sec_mda · as of 2026-08-06]
- Net loss — Net income of -$22.0M as of 2026-06-30 indicates ongoing operating losses [sec]
- Share price volatility — 1-month share price return down 9.6% as of 2026-09-27 suggests near-term market skepticism [news · published 2026-09-27]
What to watch
- Progress of JANX007 Phase 1b expansion cohorts in taxane-naïve mCRPC, combination with darolutamide, and post-PARP inhibitor patients [sec_mda · as of 2026-02-26]
- Initiation and data from the Phase 1 trial of JANX013 with JANX007 for metastatic castration-resistant prostate cancer [news · published 2026-09-27]
- Future capital requirements and potential financing needs given cash position and net loss [sec_mda · as of 2026-08-06]
- Regulatory interactions and any updates on JANX008 Phase 1/1b study in advanced or metastatic solid tumors [catalyst]
Sources: Catalysts · News · SEC MD&A · Generated September 30, 2026 · How we verify sources →
Run Janux Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Janux Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.09 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 28, 2026- % of float
- 17.5%
- Days to cover
- 6.3
- Shares short
- 7,440,069
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
JANX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Janux Therapeutics, Inc.?
Janux Therapeutics is a publicly traded biotechnology company developing TRACTr, TRACIr, and ARM platform-based therapies for oncology, with lead programs JANX007 and JANX008 in Phase 1/1b clinical trials for metastatic castration-resistant prostate cancer and solid tumors.
What is Janux Therapeutics, Inc.'s lead drug candidate?
Janux Therapeutics, Inc.'s most advanced tracked candidate is JANX007 (Phase 1) for Prostate Cancer.
Who is the CEO of Janux Therapeutics, Inc.?
Dr. David Alan Campbell Ph.D. is the chief executive officer of Janux Therapeutics, Inc. (JANX).
Where is Janux Therapeutics, Inc. headquartered?
Janux Therapeutics, Inc. (JANX) is headquartered in San Diego, CA, United States.
What therapeutic areas does Janux Therapeutics, Inc. focus on?
Janux Therapeutics, Inc. develops therapies across Oncology, Immunology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.